Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy - PubMed (original) (raw)

. 2003 Nov;88(11):5150-7.

doi: 10.1210/jc.2003-030262.

Affiliations

• PMID: 14602742
• DOI: 10.1210/jc.2003-030262

Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy

Jochen Mundschenk et al. J Clin Endocrinol Metab. 2003 Nov.

Abstract

The stable somatostatin analog octreotide has been successfully used for imaging and treatment of a variety of human tumors. In pheochromocytoma, data on somatostatin receptor subtyping have thus far been sparse. Pheochromocytomas often express more than one somatostatin receptor, and it is uncertain by which receptor subtype the functional responses of octreotide are mediated. Here, we have examined somatostatin receptor protein expression in a panel of 52 pheochromocytomas from 35 randomly selected patients by immunostaining with specific polyclonal anti-sst(1-5) and monoclonal mouse anti-SS-14 antibodies. Staining pattern, distribution and subcellular localization of somatostatin receptor subtypes were investigated. Seventeen patients received (111)In-octreotide scintigraphy. Although the vast majority of tumors (90%) showed positive immunohistochemical staining for sst(3), immunoreactive sst(2A) receptors were only seen in 13 tumors (25%). All other somatostatin receptor subtypes were less frequently detected. Interestingly, among sst(3)-positive tumors strikingly different subcellular distributions of immunoreactive sst(3) receptors were observed. In most cases, immunoreactive sst(3) receptors were distributed throughout the cytosol. Scintigraphic localization of tumors larger than 1 cm in diameter was always successful in the presence of immunoreactive sst(2A) receptors. In the absence of sst(2A), true-positive octreotide scintigraphy was only seen in the presence of membrane-associated sst(3) immunoreactivity. Our findings suggest that selective expression of functional membrane-associated sst(3) receptors is sufficient for high tracer uptake during octreotide scintigraphy in a subgroup of human pheochromocytomas. These tumors may represent a potential target treatment with somatostatin receptor agonists with improved sst(3) activity.

PubMed Disclaimer

Similar articles

• Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
  Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA. Hofland LJ, et al. J Nucl Med. 2003 Aug;44(8):1315-21. J Nucl Med. 2003. PMID: 12902423
• The biology and clinical relevance of somatostatin receptor scintigraphy in adrenal tumor management.
  Kennedy JW, Dluhy RG. Kennedy JW, et al. Yale J Biol Med. 1997 Sep-Dec;70(5-6):565-75. Yale J Biol Med. 1997. PMID: 9825485 Free PMC article. Review.
• [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.
  van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ. van der Harst E, et al. J Clin Endocrinol Metab. 2001 Feb;86(2):685-93. doi: 10.1210/jcem.86.2.7238. J Clin Endocrinol Metab. 2001. PMID: 11158032
• Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors.
  Hofland LJ, Liu Q, Van Koetsveld PM, Zuijderwijk J, Van Der Ham F, De Krijger RR, Schonbrunn A, Lamberts SW. Hofland LJ, et al. J Clin Endocrinol Metab. 1999 Feb;84(2):775-80. doi: 10.1210/jcem.84.2.5497. J Clin Endocrinol Metab. 1999. PMID: 10022452

Cited by

• Identification of Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking.
  Lehmann A, Kliewer A, Günther T, Nagel F, Schulz S. Lehmann A, et al. Mol Endocrinol. 2016 Jun;30(6):645-59. doi: 10.1210/me.2015-1244. Epub 2016 Apr 21. Mol Endocrinol. 2016. PMID: 27101376 Free PMC article.
• Expression of the Calcitonin Receptor-like Receptor (CALCRL) in Normal and Neoplastic Tissues.
  Wende B, Beyer AL, Ruhnke N, Kaemmerer D, Sänger J, Schulz S, Lupp A. Wende B, et al. Int J Mol Sci. 2023 Feb 16;24(4):3960. doi: 10.3390/ijms24043960. Int J Mol Sci. 2023. PMID: 36835377 Free PMC article.
• A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
  Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ. Kroiss A, et al. Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1800-8. doi: 10.1007/s00259-013-2548-y. Epub 2013 Sep 27. Eur J Nucl Med Mol Imaging. 2013. PMID: 24072345
• Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas.
  Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Eisenhofer G, et al. Horm Metab Res. 2008 May;40(5):329-37. doi: 10.1055/s-2008-1073156. Horm Metab Res. 2008. PMID: 18491252 Free PMC article. Review.
• Somatostatin receptor scintigraphy in thoracic diseases.
  Ameri P, Gatto F, Arvigo M, Villa G, Resmini E, Minuto F, Murialdo G, Ferone D. Ameri P, et al. J Endocrinol Invest. 2007 Nov;30(10):889-902. doi: 10.1007/BF03349233. J Endocrinol Invest. 2007. PMID: 18075294 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • SciCrunch